How well does Datroway(DatopotamabDeruxtecan-dlnk) work?

Clinical trial results demonstrating the effectiveness of DATROWAY are summarized here.

Clinical Efficacy

In the TROPION-Breast01 trial, DATROWAY showed a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy, with a median PFS of 6.9 months versus 4.9 months. The confirmed objective response rate was 36% with DATROWAY, including complete and partial responses. The median duration of response was 6.7 months. Overall survival results were not statistically significant. The study supported DATROWAY's efficacy in patients with advanced HR-positive, HER2-negative breast cancer who had prior endocrine and chemotherapy treatments.